- Home
- About Us
- Service
- Application
- Technology
- Contact Us
HapOnco® PARPrion
HapOnco® PARPrion
HRD testing helps patients benefit from PARP inhibitor treatment
Product Introduction
HapOnco® PARPrion HRD Gene Testing is a gene testing product independently developed by HaploX for guiding Poly (ADP-Ribose) Polymerase Inhibitors (PARPi). The testing content includes homologous recombination repair genes such as BRCA1/2, as well as analysis of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale State Transitions (LST). It comprehensively assesses the patient's Homologous Recombination Deficiency (HRD) status and provides a reference basis for clinical PARPi treatment.
Key features
Comprehensive HRD assessment (BRCA1/2, LOH, TAI, LST).
Identifies patients potentially benefiting from PARPi therapy.
Goes beyond BRCA mutation analysis for a broader HRD evaluation.
Identifies patients potentially benefiting from PARPi therapy.
Goes beyond BRCA mutation analysis for a broader HRD evaluation.
Applicable Population
Ovarian, breast, prostate, and pancreatic cancer patients.Solid tumor patients with poor response to conventional therapies.
Address
Units 610, 6/F, Building 16W, Phase 3, HongKong Science Park, New Territories, HongKong
Phone
+852 69410851
customer_service@haplox.net
© Copyright Job Portal 2025.
